PortalPublikationenCurrent treatment of heart failure with preserved ejection f...

Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?

Standard

Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? / Li, Jia; Becher, Peter Moritz; Blankenberg, Stefan; Westermann, Dirk.

in: CARDIOL RES PRACT, Jahrgang 2013, 2013, S. 130724.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Li, J, Becher, PM, Blankenberg, S & Westermann, D 2013, 'Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?', CARDIOL RES PRACT, Jg. 2013, S. 130724. https://doi.org/10.1155/2013/130724

APA

Li, J., Becher, P. M., Blankenberg, S., & Westermann, D. (2013). Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? CARDIOL RES PRACT, 2013, 130724. https://doi.org/10.1155/2013/130724

Vancouver

Li J, Becher PM, Blankenberg S, Westermann D. Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? CARDIOL RES PRACT. 2013;2013:130724. https://doi.org/10.1155/2013/130724

Bibtex

@article{160a7d2b17af4dc6a50c89b5e5d6eac8,
title = "Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?",
abstract = "ACCORDING TO THE EJECTION FRACTION, PATIENTS WITH HEART FAILURE MAY BE DIVIDED INTO TWO DIFFERENT GROUPS: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More importantly, despite decline in mortality after treatment in regard to current guideline in patients with heart failure with reduced ejection fraction, there are still no trials resulting in improved outcome in patients with heart failure with preserved ejection fraction so far. Thus, novel pathophysiological mechanisms are under development, and other new viewpoints, such as multiple comorbidities resulting in increased non-cardiac deaths in patients with heart failure and preserved ejection fraction, were presented recently. In this review, we will focus on the tested as well as the promising therapeutic options that are currently studied in patients with heart failure with preserved ejection fraction, along with a brief discussion of pathophysiological mechanisms and diagnostic options that are helpful to increase our understanding of novel therapeutic strategies. ",
author = "Jia Li and Becher, {Peter Moritz} and Stefan Blankenberg and Dirk Westermann",
year = "2013",
doi = "10.1155/2013/130724",
language = "English",
volume = "2013",
pages = "130724",
journal = "CARDIOL RES PRACT",
issn = "2090-8016",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?

AU - Li, Jia

AU - Becher, Peter Moritz

AU - Blankenberg, Stefan

AU - Westermann, Dirk

PY - 2013

Y1 - 2013

N2 - ACCORDING TO THE EJECTION FRACTION, PATIENTS WITH HEART FAILURE MAY BE DIVIDED INTO TWO DIFFERENT GROUPS: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More importantly, despite decline in mortality after treatment in regard to current guideline in patients with heart failure with reduced ejection fraction, there are still no trials resulting in improved outcome in patients with heart failure with preserved ejection fraction so far. Thus, novel pathophysiological mechanisms are under development, and other new viewpoints, such as multiple comorbidities resulting in increased non-cardiac deaths in patients with heart failure and preserved ejection fraction, were presented recently. In this review, we will focus on the tested as well as the promising therapeutic options that are currently studied in patients with heart failure with preserved ejection fraction, along with a brief discussion of pathophysiological mechanisms and diagnostic options that are helpful to increase our understanding of novel therapeutic strategies.

AB - ACCORDING TO THE EJECTION FRACTION, PATIENTS WITH HEART FAILURE MAY BE DIVIDED INTO TWO DIFFERENT GROUPS: heart failure with preserved or reduced ejection fraction. In recent years, accumulating studies showed that increased mortality and morbidity rates of these two groups are nearly equal. More importantly, despite decline in mortality after treatment in regard to current guideline in patients with heart failure with reduced ejection fraction, there are still no trials resulting in improved outcome in patients with heart failure with preserved ejection fraction so far. Thus, novel pathophysiological mechanisms are under development, and other new viewpoints, such as multiple comorbidities resulting in increased non-cardiac deaths in patients with heart failure and preserved ejection fraction, were presented recently. In this review, we will focus on the tested as well as the promising therapeutic options that are currently studied in patients with heart failure with preserved ejection fraction, along with a brief discussion of pathophysiological mechanisms and diagnostic options that are helpful to increase our understanding of novel therapeutic strategies.

U2 - 10.1155/2013/130724

DO - 10.1155/2013/130724

M3 - SCORING: Review article

C2 - 24251065

VL - 2013

SP - 130724

JO - CARDIOL RES PRACT

JF - CARDIOL RES PRACT

SN - 2090-8016

ER -